Capricor Therapeutics Inc Stock Price, News & Analysis

Capricor Therapeutics (NASDAQ: CAPR) announced the presentation of one-year safety and efficacy results from its HOPE-2 open-label extension study for CAP-1002, targeting Duchenne muscular dystrophy (DMD). The findings will be showcased during the World Muscle Society Congress from October 11-15, 2022, in Halifax, Canada. Linda Marbán, CEO, expressed pride in sharing this data to enhance awareness of DMD. The study's poster presentation is scheduled for October 14, 2022, highlighting a new treatment approach for muscle pathogenesis.

Capricor Therapeutics (NASDAQ: CAPR) announced its participation in upcoming investor conferences in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, from 1:30 - 2:00 p.m. ET, which includes a presentation and one-on-one meetings. Additionally, Capricor will be featured in a panel at the Cantor Fitzgerald Cell & Genetics Medicines Conference on September 15, 2022. The events will be accessible via webcast, with presentations archived on Capricor's website.

Capricor Therapeutics (NASDAQ: CAPR) has initiated the pivotal Phase 3 HOPE-3 clinical trial for CAP-1002, targeting patients with late-stage Duchenne Muscular Dystrophy (DMD). Positive results from the HOPE-2 open label extension study showcase significant improvements in muscle function. The company is pursuing FDA discussions for CAP-1002's development. Financially, Capricor reported a net loss of $7.1 million for Q2 2022, but has sufficient cash to fund operations into Q2 2024. A partnership with Nippon Shinyaku supports HOPE-3 with a $30 million upfront payment.

Capricor Therapeutics (NASDAQ: CAPR) announces it will release its financial results for the second quarter ended June 30, 2022, after market close on August 10, 2022. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics, particularly its lead candidate, CAP-1002, for treating Duchenne muscular dystrophy. More details can be found at capricor.com.

Capricor Therapeutics (NASDAQ: CAPR) has announced the start of patient dosing in the HOPE-3 Phase 3 clinical trial for CAP-1002, a cell therapy aimed at treating late-stage Duchenne muscular dystrophy (DMD). This randomized, double-blind, placebo-controlled study is set to enroll about 70 patients in the U.S. Positive results from the earlier HOPE-2 trial suggested CAP-1002 could slow the loss of upper limb function by up to 70%. A partnership with Nippon Shinyaku Co., Ltd. will support this trial's funding, while CAP-1002 holds regulatory designations that may facilitate its path to market approval.

Capricor Therapeutics (NASDAQ: CAPR) announces positive one-year results from its HOPE-2 open label extension study for CAP-1002 in non-ambulant patients with Duchenne muscular dystrophy (DMD). The study met its primary endpoint, showing significant improvements in the Performance of the Upper Limb (PUL 2.0) scale (p=0.02). CAP-1002 was administered to 20 original patients, 12 of whom completed the year-long follow-up. The FDA has granted CAP-1002 RMAT and Orphan Drug Designation. Capricor plans to present these findings to the FDA while currently conducting a Phase 3 trial (HOPE-3).

Capricor Therapeutics (NASDAQ: CAPR) announced it will present one-year results from its HOPE-2 study on June 25, 2022, at the PPMD Annual Conference in Scottsdale, Arizona. Dr. Linda Marbán will lead a late-breaking session at 5:05 p.m. MT, sharing safety and efficacy results for their lead asset CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The conference, the largest international event for DMD research, will occur from June 22-26, 2022, with an option for virtual attendance.

Capricor Therapeutics has appointed Xavier Avat as Chief Business Officer to enhance its commercial strategy for CAP-1002, which targets Duchenne muscular dystrophy. With over 25 years of experience at leading biotech firms, Avat will oversee the commercialization of Capricor's products and business development initiatives. CEO Linda Marbán emphasized Avat's potential to drive growth and strengthen the company's positioning in rare diseases. Capricor is also expanding its proprietary exosome technology as part of its therapeutic portfolio.

Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. The presentation is scheduled for May 25, 2022, at 9:30 a.m. ET. Investors can register for the event through a provided link. Capricor, focused on developing transformative cell and exosome-based therapeutics, is advancing its lead candidate, CAP-1002, for Duchenne muscular dystrophy. The company aims to create exosomes for delivering nucleic acids to treat various diseases.